Clinical Trial Update: Use of Demineralised Bone Matrix (DBX) in Osteochondritis Dissecans (OCD) [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating Demineralised Bone Matrix (DBX) for Osteochondritis Dissecans has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteochondritis Dissecans

Drugs mentioned

• DBX Demineralised Bone Matrix (demineralised bone matrix)

Snippet

Sponsor: Synthes GmbH | Conditions: Osteochondritis Dissecans | Phase 4 | Status: WITHDRAWN